XL-647
CAS No. 781613-23-8
XL-647 ( Tesevatinib;EXEL-7647;KD-019 )
Catalog No. M15946 CAS No. 781613-23-8
XL-647 (Tesevatinib, EXEL-7647, KD-019) is a novel spectrum-selective kinase inhibitor that potently inhibits the EGFR, ErbB2, KDR and EphB4 with IC50 of 0.3, 16, 1.5 and 1.4 nM, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 142 | Get Quote |
|
5MG | 224 | Get Quote |
|
10MG | 434 | Get Quote |
|
25MG | 710 | Get Quote |
|
50MG | 972 | Get Quote |
|
100MG | Get Quote | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameXL-647
-
NoteResearch use only, not for human use.
-
Brief DescriptionXL-647 (Tesevatinib, EXEL-7647, KD-019) is a novel spectrum-selective kinase inhibitor that potently inhibits the EGFR, ErbB2, KDR and EphB4 with IC50 of 0.3, 16, 1.5 and 1.4 nM, respectively.
-
DescriptionXL-647 (Tesevatinib, EXEL-7647, KD-019) is a novel spectrum-selective kinase inhibitor that potently inhibits the EGFR, ErbB2, KDR and EphB4 with IC50 of 0.3, 16, 1.5 and 1.4 nM, respectively; shows no inhibition on IGF1R and InsR, also is inactive against a panel of 55 serine-threonine kinases (including CDKs, stress-activated protein kinases, and PKC isoforms; inhibits WT and mutant EGFR phosphorylation in cells with IC50 of 5 and 74 nM, inhibits mutant EGFR resistant to gefitinib and erlotinib, inhibits cellular proliferation and EGFR pathway activation in the erlotinib-resistant H1975 cell line that harbors double mutation L858R/T790M; inhibits H1975 xenograft tumors and reduces both tumor EGFR signaling and tumor vessel density in vivo.Lung Cancer Phase 3 Clinical
-
SynonymsTesevatinib;EXEL-7647;KD-019
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research AreaCancer
-
IndicationLung Cancer
Chemical Information
-
CAS Number781613-23-8
-
Formula Weight491.40
-
Molecular FormulaC24H25Cl2FN4O2
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 30 mg/mL
-
SMILESO=C(NC1=CC=C(CCN2CC3=C(C=C(OC)C(OC)=C3)CC2)C=C1)C4=CC=CC(/C=C(C(N(C)/C5=C\C6=CC=CC=C6)=O)\NC5=O)=C4
-
Chemical Name4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-[[(3aα,5β,6aα)-octahydro-2-methylcyclopenta[c]pyrrol-5-yl]methoxy]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Pietanza MC, et al. J Thorac Oncol. 2012 Jan;7(1):219-26.
2. Gendreau SB, et al. Clin Cancer Res. 2007 Jun 15;13(12):3713-23.
2. Gendreau SB, et al. Clin Cancer Res. 2007 Jun 15;13(12):3713-23.
molnova catalog
related products
-
EGFR-IN-7
EGFR-IN-7 is a selective and potent EGFR kinase inhibitor.TQB3804 displayed potent enzymatic activities for EGFRd746-750/T790M/C797S, EGFRL858R/T790M/C797S, EGFRd746-750/T790M, and EGFRL858R/T790M with IC50 of 0.46, 0.13, 0.26, and 0.19 nM respectively, and has similar enzymatic activity for EGFRWT (IC50 = 1.07) to Osimertinib.
-
Withanolide A
Withanolide A extends the lifespan in human EGFR-driven cancerous Caenorhabditis elegans.
-
EGFR/ErbB2 Inhibitor
EGFR/ErbB2 Inhibitor is a cell-permeable inhibitor of EGFR and c-ErbB2 (IC50s = 20 and 79 nM, respectively)